glow ghk-cu tb-500 bpc-157 Glow) 10mg + 10mg + 50mg Glow Blend (GHK-Cu, BPC-157, TB-500)

AOD 9604 has been studied in humans, and the results are best described as modest rather than miraculous

New England Journal of Medicine: Retatrutide Phase 2 trial results - The landmark study establishing retatrutide efficacy and safety across multiple dose groups New England Journal of Medicine: STEP 1 semaglutide trial results - The pivotal trial demonstrating semaglutide 2.4 mg weight loss efficacy ClinicalTrials.gov: Retatrutide TRIUMPH program - Current status and details of all ongoing Phase 3 retatrutide trials FDA prescribing information for Wegovy (semaglutide 2.4 mg) - Complete approved labeling including dosing, safety, and clinical data New England Journal of Medicine: SELECT cardiovascular outcomes trial - The trial demonstrating semaglutide 20% reduction in major cardiovascular events These primary sources should be the foundation for any serious evaluation of either compound

You may also notice the completely benign side effect of pinkish or reddish urine

Unlike many peptides, BPC-157 is not strongly weight-dependent

What Changed in 2026 In early 2026, the government announced plans to let about 14 peptides including BPC157 and TB500 be made again by licensed pharmacies with a doctors prescription